Compare ADMA Biologics Inc (ADMA) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs NRG Energy Inc — how do they compare? ADMA Biologics Inc trades at $10.45 (market cap $2.31B), while NRG Energy Inc trades at $101.29 (market cap $22.53B). The key difference: NRG Energy Inc is far larger — about 9.8× ADMA Biologics Inc's market cap, and NRG Energy Inc pays a 1.77% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ADMA Biologics Inc for 18 Days and NRG Energy Inc for 63 Days on average.
| ADMA | NRG | |
|---|---|---|
Market Cap | $2.31B | $22.53B |
Volume | 3,763,154 | 2,965,287 |
Sector | Health | Utilities |
52-Week High | $20.38 | $184.03 |
52-Week Low | $7.60 | $95.23 |
Typical Hold Time | 18 Days | 63 Days |
Enterprise Value | $2.38B | $46.49B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA Biologics trades at $10.415, up 2.31% today, showing strong profitability with 32.98% net income margin and 41.9% ROE. Technical indicators are bullish overall, though recent earnings missed expectations in Q1 and Q2 2026. The company faces legal investigations regarding fiduciary duties, creating investor uncertainty despite analyst optimism.
Wall Street maintains strong bullish sentiment with 90% buy ratings and an $18.67 consensus price target, representing 79% upside potential. Key risks include ongoing legal challenges and recent earnings misses, while fundamentals remain solid with projected revenue growth and improved cash flow in 2026.
NRG Energy trades at $106.37, down 1.48% on the day, with mixed technical signals showing neutral overall momentum. The stock demonstrates strong profitability with 26.77% ROE and attractive valuation at 0.66 P/S ratio, though recent Q2 2026 earnings missed expectations. The company is executing a growth strategy centered on a 1.2-GW Texas data center power project, with analyst consensus strongly bullish at 70% buy ratings and $202.90 price target representing significant upside potential from current levels.
NRG presents a compelling investment case with strong analyst support and strategic growth initiatives, though investors face risks from recent earnings misses, elevated debt levels at 56.42% debt-to-asset ratio, and execution challenges in major capital projects. The stock's current valuation disconnect between strong analyst targets and recent price weakness creates potential opportunity for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
